이중특이성항체 치료제 수탁제조 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 적응증별, 투여 경로별, 최종 용도별, 지역별, 경쟁별(2020-2030년)
Bispecific Antibody Therapeutics Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Route of Administration, By End Use, By Region & Competition, 2020-2030F
상품코드:1748749
리서치사:TechSci Research
발행일:2025년 06월
페이지 정보:영문 190 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 이중특이성항체 치료제 수탁제조 시장은 2024년에는 73억 2,000만 달러로 평가되며, 2030년에는 187억 4,000만 달러에 달하며, CAGR 16.92%로 성장할 것으로 예측됩니다.
이중특이성항체는 두 개의 서로 다른 항원을 동시에 표적으로 삼는 능력으로 암이나 자가면역질환과 같은 복잡한 질병에 대한 새로운 치료 전략을 제공함으로써 바이오의약품 업계에서 큰 지지를 받고 있습니다. 수탁제조기관(CMO)은 이러한 복잡한 생물제제 제조에 필요한 인프라, 기술 전문성, 확장성을 제공함으로써 이러한 상황에서 중요한 역할을 담당하고 있습니다. 이 시장을 주도하는 것은 빠르게 성장하는 이중특이성항체 후보물질의 파이프라인과 많은 바이오기업이 아웃소싱을 선호하는 전문 제조 역량에 대한 필요성입니다. 기업이 혁신적인 이중특이성항체 포맷과 치료 용도를 계속 개발함에 따라 유연하고 고품질의 제조 지원에 대한 수요는 꾸준히 증가할 것으로 예상되며, 차세대 생물학적 치료제를 추진하는 데 있으며, CMO의 역할이 강화될 것으로 예측됩니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
73억 2,000만 달러
시장 규모 : 2030년
187억 4,000만 달러
CAGR : 2025-2030년
16.92%
급성장 부문
자기 염증성 질환 및 자가면역질환
최대 시장
북미
시장 성장 촉진요인
이중특이성항체 치료제에 대한 지속적인 연구 활동 진행
주요 시장 이슈
이중특이성항체 치료제 제조 관련 과제
주요 시장 동향
이중특이성항체에 대한 수요 증가
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 이중특이성항체 치료제 수탁제조 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
적응증별(암, 감염증, 자기 염증성 및 자가면역성 질환, 중추신경계 질환, 기타)
투여 경로별(정맥내, 피하, 기타)
최종 용도별(제약회사, 바이오의약품 회사, 기타)
기업별(2024)
지역별
시장 맵
제6장 북미의 이중특이성항체 치료제 수탁제조 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 이중특이성항체 치료제 수탁제조 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 이중특이성항체 치료제 수탁제조 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 이중특이성항체 치료제 수탁제조 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 이중특이성항체 치료제 수탁제조 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제13장 PESTEL 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Lonza Group AG
Creative Biolabs Inc
Amgen Inc
Johnson & Johnson
Wuxi Biologics Cayman Inc
Roche Holding AG
Sino Biological Inc
IQVIA Inc
Janssen Pharmaceuticals Inc
AbbVie Inc.
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Bispecific Antibody Therapeutics Contract Manufacturing Market was valued at USD 7.32 billion in 2024 and is projected to reach USD 18.74 billion by 2030, growing at a CAGR of 16.92%. Bispecific antibodies have gained significant traction in the biopharmaceutical industry for their ability to target two different antigens simultaneously, offering novel therapeutic strategies for complex diseases such as cancer and autoimmune disorders. Contract manufacturing organizations (CMOs) play a crucial role in this landscape by providing the infrastructure, technical expertise, and scalability required to manufacture these complex biologics. The market is being driven by a rapidly expanding pipeline of bispecific antibody candidates and the need for specialized manufacturing capabilities that many biopharma companies prefer to outsource. As companies continue to develop innovative bispecific formats and therapeutic applications, the demand for flexible, high-quality manufacturing support is expected to rise steadily, reinforcing the role of CMOs in advancing next-generation biologic therapies.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 7.32 Billion
Market Size 2030
USD 18.74 Billion
CAGR 2025-2030
16.92%
Fastest Growing Segment
Autoinflammatory and Autoimmune Diseases
Largest Market
North America
Key Market Drivers
Ongoing Research Activities in Bispecific Antibody Therapeutics
The Global Bispecific Antibody Therapeutics Contract Manufacturing Market is experiencing strong growth due to intensifying research and development efforts. As of early 2025, there are more than 200 bispecific antibody candidates in various stages of development, with over 50 undergoing clinical trials targeting oncology, autoimmune conditions, and infectious diseases. The structural diversity of bispecific formats-such as BiTEs, DVD-Igs, and tandem diabodies-requires advanced design and production capabilities. CMOs with expertise in bispecific antibody manufacturing are increasingly in demand as they provide essential services like high-throughput analytics, improved purification processes, and scalable production systems. With more than 60% of biologics-focused CMOs having expanded capabilities tailored to bispecifics, the sector is seeing a surge in specialized offerings aimed at supporting the growing complexity and volume of these novel therapeutics.
Key Market Challenges
Challenges Associated with Manufacturing of Bispecific Antibody Therapeutics
Manufacturing bispecific antibody therapeutics presents a unique set of challenges that differentiate them from traditional monoclonal antibodies. The complexity of these molecules-arising from their dual-target structure-necessitates precise control over manufacturing to ensure consistency and efficacy. Post-translational modifications such as glycosylation and oxidation introduce further heterogeneity, requiring robust analytical oversight. Scale-up remains a critical hurdle, as production must transition smoothly from development to commercial levels without compromising quality. Custom purification strategies are often required due to the distinct molecular properties of each bispecific antibody, complicating downstream processing. Additionally, the need for specialized equipment, such as bioreactors and chromatography systems suited for bispecifics, results in higher capital investment. Regulatory compliance adds another layer of complexity, as evolving global guidelines demand rigorous quality and safety controls, further elevating the operational demands for CMOs in this field.
Key Market Trends
Increasing Demand for Bispecific Antibodies
The rising demand for bispecific antibodies is a dominant trend shaping the Global Bispecific Antibody Therapeutics Contract Manufacturing Market. These molecules offer the ability to engage two targets simultaneously, providing novel mechanisms of action in diseases like cancer, autoimmune disorders, and infections. In oncology, bispecific T-cell engagers (BiTEs) have shown strong therapeutic potential by redirecting immune responses toward cancer cells, prompting further clinical exploration. The trend toward personalized medicine is also driving demand for customizable bispecific formats tailored to specific disease subtypes or patient groups. As biopharmaceutical companies seek contract partners capable of delivering precision-engineered therapeutics at scale, the market for CMOs offering flexible and advanced bispecific antibody manufacturing continues to grow. This rising demand, coupled with innovations in therapeutic design, is positioning bispecific antibodies as a key area of growth within the broader biologics manufacturing ecosystem.
Key Market Players
Lonza Group AG
Creative Biolabs Inc
Amgen Inc
Johnson & Johnson
Wuxi Biologics Cayman Inc
Roche Holding AG
Sino Biological Inc
IQVIA Inc
Janssen Pharmaceuticals Inc
AbbVie Inc
Report Scope:
In this report, the Global Bispecific Antibody Therapeutics Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Bispecific Antibody Therapeutics Contract Manufacturing Market, By Indication:
Cancer
Infectious Diseases
Autoinflammatory and Autoimmune Diseases
CNS Conditions
Others
Bispecific Antibody Therapeutics Contract Manufacturing Market, By Route of Administration:
Intravenous
Subcutaneous
Others
Bispecific Antibody Therapeutics Contract Manufacturing Market, By End Use:
Pharmaceutical Companies
Biopharmaceutical Companies
Others
Bispecific Antibody Therapeutics Contract Manufacturing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibody Therapeutics Contract Manufacturing Market.
Available Customizations:
Global Bispecific Antibody Therapeutics Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customers
5. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Cancer, Infectious Diseases, Autoinflammatory and Autoimmune Diseases, CNS Conditions, Others)
5.2.2. By Route of Administration (Intravenous, Subcutaneous, Others)
5.2.3. By End Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
5.2.4. By Company (2024)
5.2.5. By Region
5.3. Market Map
6. North America Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indications
6.2.2. By Route of Administration
6.2.3. By End Use
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indications
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By End Use
6.3.2. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indications
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By End Use
6.3.3. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indications
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By End Use
7. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indications
7.2.2. By Route of Administration
7.2.3. By End Use
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indications
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By End Use
7.3.2. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indications
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By End Use
7.3.3. United Kingdom Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indications
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By End Use
7.3.4. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indications
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By End Use
7.3.5. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indications
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By End Use
8. Asia-Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indications
8.2.2. By Route of Administration
8.2.3. By End Use
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indications
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By End Use
8.3.2. India Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indications
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By End Use
8.3.3. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indications
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By End Use
8.3.4. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indications
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By End Use
8.3.5. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indications
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By End Use
9. South America Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indications
9.2.2. By Route of Administration
9.2.3. By End Use
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indications
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By End Use
9.3.2. Argentina Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indications
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By End Use
9.3.3. Colombia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indications
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By End Use
10. Middle East and Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indications
10.2.2. By Route of Administration
10.2.3. By End Use
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indications
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By End Use
10.3.2. Saudi Arabia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indications
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By End Use
10.3.3. UAE Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
